XTalks

FEBRUARY 27, 2024

Iovance Biotherapeutics’ Amtagvi (lifileucel) won US Food and Drug Administration (FDA) approval last week for the treatment of advanced melanoma, making it the first individualized tumor-infiltrating lymphocyte (TIL) therapy and the first T-cell therapy for a solid tumor to win US regulatory approval.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

XTalks

JANUARY 28, 2022

Kimmtrak is part of a novel class of bispecific T cell immunotherapies being developed by Immunocore. Kimmtrak has also become the first bispecific T cell engager to be FDA-approved for the treatment of a solid tumor. Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. Utilizing Clover’s proprietary Trimer-Tag © technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Drug Discovery World

JUNE 14, 2023

We are a cell therapy company that uses a very specific receptor to engineer T cells and administer these engineered T cells back to solid tumour patients. We consider ourselves a next-generation engineered cell therapy company. AB : I think it is accomplishing on cell therapy in solid tumours as a whole.

Research 52

Research Engineer In-Vivo Production 52

pharmaphorum

AUGUST 25, 2022

The double-headed antibody binds to CD3 on T cells and redirects them to BCMA-expressing myeloma cells, with the aim of stimulating an immune attack on the tumour, which remains incurable despite a slew of new therapies reaching the market in recent years.

Antibody 98

Antibody Marketing Drugs Medicine 98

pharmaphorum

APRIL 5, 2022

Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the European Commission. It’s the first treatment for mUM in the EU, as well as the first BiTE drug to treat a solid tumour.

Protein 52

Protein Sales Drugs Trials 52

pharmaphorum

JANUARY 18, 2022

Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs. Researchers at Almirall have identified several proteins whose abnormal function is associated with inflammatory immune skin diseases.

Dermatology 52

Dermatology Protein Pharma Companies Research 52

Delveinsight

FEBRUARY 25, 2021

Beam employs three approaches to deliver its genetic medicines to cells. Electroporation is used for ex vivo delivery of therapies to blood and immune cells. The GuideTx technology screens for lipid nanoparticles inside the body that can be used to deliver RNA to cells throughout the body.

DNA 52

DNA In-Vivo Genetics Medicine 52

The Pharma Data

MARCH 23, 2022

Their investigation reveals that an experimental drug that targets GSPT1 for degradation can also halt Ebola virus infection in human cells. who co-led the Cell Reports study with Scripps Research Professor Juan Carlos De La Torre, Ph.D., The team found that polymerase succeeds by biding its time in host cells.

Protein 52

Protein Genome Genomics Research 52

pharmaphorum

FEBRUARY 22, 2021

Last week, Bluebird said it was pausing its Zynteglo (betibeglogene autotemcel) programme in Europe after a phase 1/2 trial in patients with sickle cell disease (SCD) – another red blood cell disorder – turned up two cases of blood cancers, one of acute myeloid leukaemia (AML) and another of myelodysplastic syndrome (MDS).

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. CellCentric, a U.K-based

Development 52

Development Drugs Clinical Development Antibody 52

pharmaphorum

JANUARY 5, 2021

Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Immune Response 52

Immune Response FDA Approval Drugs Sales 52

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. About Trimer-Tag© Technology. S-Trimer is intended to be adjuvanted. Food and Drug Administration (FDA).

Vaccination 52

Vaccination Vaccine Trials Protein 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Hoffmann-La Roche is the leading patent filer in the peptide nano-particle conjugates space.

Antibody 130

Antibody DNA Development Vaccination 130

World of DTC Marketing

DECEMBER 13, 2021

As cancer survival rates rise, so do the price tags of life-saving treatments. Cancers occur at the cellular level, with abnormal cells dividing and spreading. OPENING: American cancer patients spent more than $21 billion on their care in 2019. billion included out-of-pocket costs of $16.22 billion and patient time costs of $4.87

Drugs 55

Drugs FDA Approval Medicine Containment 55

The Pharma Data

OCTOBER 21, 2020

The disease is a subtype of ALL in which the cancer cells have a genetic abnormality called the Philadelphia chromosome (Ph). Aggressive chemo can substantially lower blood cell counts, which may leave patients vulnerable to infections or in need of multiple blood transfusions, explained Dr. Jae Park.

Drugs 52

Drugs Genetics Trials Research 52

The Pharma Data

OCTOBER 21, 2020

The disease is a subtype of ALL in which the cancer cells have a genetic abnormality called the Philadelphia chromosome (Ph). Aggressive chemo can substantially lower blood cell counts, which may leave patients vulnerable to infections or in need of multiple blood transfusions, explained Dr. Jae Park.

Drugs 52

Drugs Genetics Trials Research 52

The Pharma Data

APRIL 22, 2023

The modified antibodies have been tested in human cells and with mice. Many antibodies used to treat covid infection during the pandemic have been so-called neutralizing antibodies that prevent the virus from infecting the cell. The studies were carried out in human cells and with mice.

Antibody 40

Antibody Immune Response Protein Research 40

XTalks

JANUARY 19, 2024

Therapeutic radiopharmaceuticals deliver beta or alpha radiation, which destroys diseased cells, such as cancer cells. The aim of these compounds is to deliver radiation directly to the tumor cells, minimizing damage to surrounding healthy tissues. In 1997, bismuth-213 was the first alpha emitter to be used clinically.

DNA 66

DNA Radiology FDA Approval Development 66

Drug Discovery World

NOVEMBER 9, 2023

Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’. Damian Trojanowski, Dr, R&D Specialist, Antibody Discovery Group, Pure Biologics, on: ‘Anti-GARP/TGFb1 antibodies in new twist – multifunctional shapers of anti-tumour immunity’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

pharmaphorum

MARCH 27, 2022

While drugs like Blenrep and teclistamab need to be administered intermittently, CAR-Ts are complex, “one and done” therapies made from a patient’s own immune cells, with a hefty price tag to match.

Antibody 98

Antibody Clinical Trials Clinical Trials Sales 98

Delveinsight

DECEMBER 3, 2020

Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. An overactivity of complement damages cells in the macula in geographic atrophy. Merck chooses TriNKET cancer immunotherapy program.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Drug Discovery World

NOVEMBER 13, 2023

Enkelejda Miho, PhD, Professor, University of Applied Sciences and Arts Northwestern Switzerland, and Managing Director, aiNET, on: ‘The singular immune response to dengue and machine learning identification of antibodies in high-throughput sequences’.

Protein 59

Protein Antibody Engineer Scientist 59

XTalks

NOVEMBER 27, 2021

The technical advisory group on SARS-CoV-2 virus evolution (TAG-VE) met on Friday to discuss B.1.1.529, The binding of the spike protein to receptors on human cells is the first and critical step of viral entry into host cells. 1.1.529, to be a variant of concern (VOC) and has named it after the Greek letter Omicron (O).

Vaccination 97

Vaccination Vaccine Protein Scientist 97

Drug Discovery World

OCTOBER 21, 2022

Take, for example, its use for CD4 T cell counting to facilitate HIV monitoring. Flow cytometry is a technique used to rapidly analyse single cells in order to characterise their physical, chemical and biological properties. . Overview, evolution, trends .

Reagent 52

Reagent Antibody Drugs Protein 52

XTalks

FEBRUARY 11, 2021

The Hershey-Chase experiment was actually a set of experiments conducted by Hershey and Chase that helped them conclude that DNA served as the genetic material of a cell. Bacteriophages inject their DNA into cells but not protein, which is mainly a constituent of their outer envelope, or capsid.

Genetics 119

Genetics DNA Genome Genomics 119

The Pharma Data

MAY 5, 2021

. Athenex shares soar with buyout of natural killer T cell player ( Endpoints ). Esker, a new biotech startup, launches with plans to make targeted immune drugs ( BioPharma Dive ). AbbVie’s Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along ( Fierce ).

Vaccination 52

Vaccination Vaccine Gene Therapy Contract Packaging 52

The Pharma Data

MAY 4, 2021

and developed Europe following the approvals in 2019 for combinations of certain immune checkpoint inhibitors and Inlyta for the first-line treatment of patients with advanced renal cell carcinoma; as well as. Inlyta globally, up 34% operationally, primarily reflecting increased demand in the U.S. and South African variants.

Vaccination 40

Vaccination Vaccine Production Sales 40